numab

Numab Therapeutics and Kaken Pharmaceutical Enter Collaborationand Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel DiseaseNumab Therapeutics and Kaken Pharmaceutical Enter Collaborationand Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease

Numab Therapeutics and Kaken Pharmaceutical Enter Collaborationand Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease

Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in…

4 months ago